Teva Pharmaceuticals
TEVA
440 hedge funds and large institutions have $5.55B invested in Teva Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 130 increasing their positions, 139 reducing their positions, and 48 closing their positions.
6% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 139
1.45% less ownership
Funds ownership: 52.29% → 50.84% (-1.5%)
2% less funds holding
Funds holding: 451 → 440 (-11)
14% less call options, than puts
Call options by funds: $268M | Put options by funds: $310M
16% less capital invested
Capital invested by funds: $6.6B → $5.55B (-$1.06B)
19% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 48
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
+$42.1M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$33.9M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$29.4M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$20.5M |
| 5 |
Citigroup
New York
|
+$16.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$63.9M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$50.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$48.8M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$39M |
| 5 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$32.4M |
TEVA Hedge Fund Activity: Q2 2021 in Review
440 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2021, worth a combined $5.55B — down 16% from $6.6B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of TEVA and 39 opened new positions — a net loss of 9 holders — while 139 trimmed existing stakes and 130 added.
The largest buyer was Legal & General Group, adding an estimated $42.1M. The largest seller was Capital Research Global Investors, cutting an estimated $63.9M.
- 440 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2021, down from 451 in Q1 2021.
- Funds reported $5.55B of Teva Pharmaceuticals stock for Q2 2021, down 16% quarter-over-quarter.
- 39 funds opened new Teva Pharmaceuticals positions in Q2 2021 and 48 closed out, a net change of -9 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2021 was Legal & General Group, an estimated $42.1M added.
- The largest Teva Pharmaceuticals seller in Q2 2021 was Capital Research Global Investors, an estimated $63.9M sold.
Based on aggregated 13F filings for Q2 2021.